Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;8(12):1170-1172.
doi: 10.1016/S2213-2600(20)30503-8. Epub 2020 Oct 29.

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

Michael A Matthay  1 , B Taylor Thompson  2
Affiliations

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

Michael A Matthay et al. Lancet Respir Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Comment in

References

    1. The Recovery Collaborative Group. Horby P, Lim WS. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. published online July 17. - DOI - PMC - PubMed
    1. Lamontagne F, Agoritsas T, Macdonald H. A living WHO guideline on drugs for covid-19. BMJ. 2020;370 - PubMed
    1. Dequin PF, Heming N, Meziani F. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298–1306. - PMC - PubMed
    1. Tomazini BM, Maia IS, Cavalcanti AB. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–1316. - PMC - PubMed
    1. Angus DC, Derde L, Al-Beidh F. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–1329. - PMC - PubMed

MeSH terms